Spirtos NM, et al. - In patients with advanced-stage endometrial cancer (EC), researchers ascertained whether the addition of paclitaxel (P) to cisplatin and doxorubicin (CD) after surgical debulking and volume-directed radiation therapy improved long-term, recurrence-free survival (RFS) and overall survival (OS). According to findings, no significant difference was found between treatment arms (CD +/− P). Subgroup analysis showed a trend towards better RFS and OS in patients treated with CDP and extended field radiotherapy, both in the initial and current reports. This long-term outcome assessment also recognized the need for continuing cancer screening to be provided to patients registered in studies.